SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab launches Neostigmine Methylsulfate Injection in US

14 Sep 2018 Evaluate

Dr. Reddy's Laboratories has launched Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection in the US market, approved by the US Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had US sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health. Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1280.00 0.30 (0.02%)
12-May-2026 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1868.85
Dr. Reddys Lab 1280.00
Cipla 1300.60
Zydus Lifesciences 948.80
Lupin 2248.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×